Cargando…
ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
ENaC inhibition with BI 1265162 is a promising strategy to optimise outcomes in patients with CF either eligible, or ineligible, for CFTR modulator therapy. Phase II clinical trials of BI 1265162 must now show this translates into clinical benefit. https://bit.ly/2OQ1IUI
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758539/ https://www.ncbi.nlm.nih.gov/pubmed/32732328 http://dx.doi.org/10.1183/13993003.00946-2020 |
| _version_ | 1783626963194216448 |
|---|---|
| author | Mall, Marcus A. |
| author_facet | Mall, Marcus A. |
| author_sort | Mall, Marcus A. |
| collection | PubMed |
| description | ENaC inhibition with BI 1265162 is a promising strategy to optimise outcomes in patients with CF either eligible, or ineligible, for CFTR modulator therapy. Phase II clinical trials of BI 1265162 must now show this translates into clinical benefit. https://bit.ly/2OQ1IUI |
| format | Online Article Text |
| id | pubmed-7758539 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | European Respiratory Society |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-77585392020-12-31 ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies Mall, Marcus A. Eur Respir J Research Highlights ENaC inhibition with BI 1265162 is a promising strategy to optimise outcomes in patients with CF either eligible, or ineligible, for CFTR modulator therapy. Phase II clinical trials of BI 1265162 must now show this translates into clinical benefit. https://bit.ly/2OQ1IUI European Respiratory Society 2020-12-24 /pmc/articles/PMC7758539/ /pubmed/32732328 http://dx.doi.org/10.1183/13993003.00946-2020 Text en Copyright ©ERS 2020 http://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. |
| spellingShingle | Research Highlights Mall, Marcus A. ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies |
| title | ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies |
| title_full | ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies |
| title_fullStr | ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies |
| title_full_unstemmed | ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies |
| title_short | ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies |
| title_sort | enac inhibition in cystic fibrosis: potential role in the new era of cftr modulator therapies |
| topic | Research Highlights |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758539/ https://www.ncbi.nlm.nih.gov/pubmed/32732328 http://dx.doi.org/10.1183/13993003.00946-2020 |
| work_keys_str_mv | AT mallmarcusa enacinhibitionincysticfibrosispotentialroleintheneweraofcftrmodulatortherapies |